How to bid in this country: portals, deadlines, thresholds →
Conclusion of non-exclusive discount agreements pursuant to § 130a para. 8 SGB V on medicinal products (open-house procedure)
Abschluss von nicht exklusiven Rabattverträgen gemäß § 130a Abs. 8 SGB V zu Arzneimitteln (Open-House-Verfahren) — original title
Your path to submission
- Deadline: 20 October 2027 at 23:59 — 354 days left.
- You submit on Vergabemarktplatz (cosinex) — not here and not by e-mail. ↗ Free bidder account on the cosinex platform required (created instantly); offers go through the bidding tool, usually plain text form suffices — no qualified signature. Sort out account and signature first — not on submission day.
- Offer and evidence in: German.
- Collect your evidence — use the eligibility analysis on this page: it lists the requirements and, for known certificates, how to get them.
What the buyer is looking for
The procurement requirement includes all medicinal products containing the active substances listed in Appendix 3 to the conditions of participation (so-called list of active substances and deadlines). Contracts can be concluded for individual active substances. Procurement needs were not divided into lots. This is an open house procedure. Insofar as wordings are used in the context of this notice which indicate the classification of procurement needs into one or more lot(s), this is solely due to the requirements of this notice form. In this context, reference is made to the non-applicability of public procurement rules as described in point 2.1 above. The AOK starts the open-house process with the following active ingredients (so-called start-up active ingredients): Item 1 of Annex 3 to the Conditions of Participation: Adalimumab; Item No 2: Beclometason dipropionate + formoterol…
Show full description
… hemifumarate-1 water in inhalation powder dosage forms, with strengths 100/6 µg and 200/6 µg, and dosieraerosol/inhalate with strength 200/6 µg; Item No 3: Betamethasone valerate + fusidic acid 0.5 water; Item No 4: dimethyl fumarate; Item No 5: Etanercept; Item No 6: Filgrastim; Item No 7: Follitropin alfa; Item No 8: Infliximab; Item No 9: lanthanum(III) ion; Item No 10: latanoprost + timolol hydrogenmaleate; Item 11: Leuprorelin acetate; Item 12: Lipegfilgrastim; Item No 13: Mesalazine in strengths of 500 mg, 1000 mg, 1200 mg, 1500 mg, 2000 mg, 3000 mg, 4000 mg; Item No 14: Naproxen; Item No 15: Natalizumab; Item 16: octreotide (depot); Item No 17: Omalizumab; Item No 18: Oxycodone hydrochloride + naloxone hydrochloride 2 water; Item No 19: Pegfilgrastim; Item No 20: Raltegravir; Item No 21: Ranibizumab; Item No 22: Rasagilin; Item 23: rotigotine; Item No 24: Ticagrelor; Item No 25: Tocilizumab; Item No 26: Ustekinumab. AOK reserves the right to adjust the procurement requirements of this open-house procedure in the course of the further procedure by supplementing Annex 3 with additional active substances or by reducing individual active substances of Annex 3. In the event of an expansion of procurement requirements, discount contracts for medicinal products containing these other active substances would also become the subject of the present open-house procedure. Of course, this would not extend the content of already concluded contracts for other active substances, but rather a new contract must be concluded (see also sections A.I.1 and A.III.4 of the conditions of participation). If the contracting authority wishes to terminate all rebate agreements for an active substance from Appendix 3, it may declare them to all rebate contractual partners for that active substance at the same date of termination and cancel the open-house procedure for the same active substance. In that case, the AOK shall immediately publish the repeal of that open-house procedure for the same active substance in the Supplement to the Official Journal of the European Union. Alternatively, the customer is entitled to conclude rebate contracts for the same active ingredient after subsequent announcement (at once) with changed conditions. If the AOK decides to adjust the procurement requirements, it will publish this fact in a further contract notice in the Supplement to the Official Journal of the European Union (so-called subsequent notice) which refers to the contract notice made in this procedure (so-called initial notice). For further information on a possible adjustment of procurement needs, please refer to the conditions of participation (Section A.I.4.1). Contracts for medicinal products containing the starting agents will be concluded at the earliest with effect from 1.1.2026. All discount contracts concluded under this open-house procedure end uniformly on 31.12.2027. In order to start the contract as soon as possible on 1.1.2026, interested companies must submit an application in accordance with the participation documents by 20.11.2025 at the latest.
Contract
Type of service
Clement What the numbers say about this buyer
- In this sector the buyer awards roughly every month (764 awards, most recently October 2026) — the next award is due around December 2026 by that rhythm. The last award went to GlaxoSmithKline GmbH & Co. KG.n = 764
- The award came in at a median 50% of the estimated value (15 awards with both estimate and value) — pricing at the estimate is usually too high here. Sector: 87%.n = 15
- The median procedure drew 5 bids (958 procedures with a bid count); 37% ended with a single bidder. Sector: median 2 bids.n = 958
- 66% of this buyer's awards went to companies that had already won here before (969 awards since 2018, spread over 328 companies). 34% went to new names.n = 969 awards since 2018
- 65% of the bids received came from small and medium-sized enterprises (77 procedures with a bid mix). Sector: 38%.n = 77
From this buyer's documented awards; comparison values from the same sector and country. Not a forecast, not legal advice. As of 01/11/2026.
What you must prove — eligibility criteria
Gemäß § 130a Abs. 8 SGB V kommen als Vertragspartner der Auftraggeberin nur pharmazeutische Unternehmer i. S. d. §§ 130a Abs. 8 SGB V, 78 Abs. 3 Satz 1 AMG oder Bewerbergemeinschaften bestehend aus pharmazeutischen Unternehmern i. S .d. vorgenannten Vorschrift… read in fullcollapse
Mit Unternehmen, die einen Bezug zu Russland im Sinne des Art. 5k Abs. (1) der Verordnung (EU) Nr. 833/2014 über restriktive Maßnahmen angesichts der Handlungen Russlands, die die Lage in der Ukraine destabilisieren (in der jeweils aktuell geltenden Fassung) a… read in fullcollapse
Es ist jeweils ein Auszug aus der Arzneimittel-Faktendatenbank (Am-FDB) der AmAnDa-Datenbank, der Arzneimitteldatenbank des BfArm, für sämtliche angebotsgegenständlichen Arzneimittel und ggf. geeigneter ergänzender Nachweise (siehe Abschnitt A.I.8 und B.3 der … read in fullcollapse
Tender documents — direct download
Who has won at this buyer so far
Across all contract types of this buyer — not just this sector. A city buys software and fire engines through the same purchasing office.
| Company | Awards | Period |
|---|---|---|
| Hexal AG · Holzkirchen | 18 | 2017–2025 |
| Novartis Pharma GmbH · Nürnberg | 16 | 2013–2026 |
| Zentiva Pharma GmbH · Frankfurt am Main | 16 | 2021–2026 |
| Bayer Vital GmbH · Leverkusen | 15 | 2013–2026 |
| betapharm Arzneimittel GmbH · Augsburg | 14 | 2021–2026 |
How often this buyer tenders this kind of work
Contracting authority contact
Tactics
When this buyer has awarded in this sector, usually 12 or more bids came in. Many compete here — price and references decide. (Based on 809 completed awards — not a statement about this procedure.)
This procedure allows 735 days between publication and deadline — typical in this country is 32 (median of 20,496 procedures). Much more generous than usual — time for a thorough bid rather than a quick one.
Foreign bidders
In Germany · Medical equipment & pharma, 270 contracts went to foreign companies over the last 3 years (of 22,355 recorded awards) — mostly from Austria, Netherlands, France.
Submission language: German.
How to bid
Don't miss the next one
Friedrich finds tenders like this for you — every morning at 7:30, each one checked by Claude (Anthropic) for fit, and he learns from your feedback what your company really does.
Register now